Scarica l'app Stockscreener
4.05
1.25%
0.05
Dopo l'orario di chiusura:
4.07
0.02
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.00
Aprire:
$4.1
Volume 24 ore:
629.62K
Relative Volume:
1.05
Capitalizzazione di mercato:
$124.26M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-3.0172
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
-3.80%
1M Prestazione:
+39.18%
6M Prestazione:
+95.65%
1 anno Prestazione:
+34.11%
Intervallo 1D:
$3.98
$4.33
Intervallo di 1 settimana:
$3.82
$4.33
Portata 52W:
$1.90
$4.39
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta VTGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
4.05 | 123.03M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Vistagen to Present at The Menopause Society 2025 Annual Meeting - Stock Titan
Tools to assess Vistagen Therapeutics Inc.’s risk profile2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Applying Elliott Wave Theory to Vistagen Therapeutics Inc.Trend Reversal & Low Risk Entry Point Guides - newser.com
Will Vistagen Therapeutics Inc. stock gain from strong economyMarket Movement Recap & Expert Approved Momentum Ideas - newser.com
What institutional flow reveals about Vistagen Therapeutics Inc.July 2025 Trade Ideas & Real-Time Volume Trigger Notifications - newser.com
How to recover losses in Vistagen Therapeutics Inc. stockPortfolio Return Report & Free Technical Confirmation Trade Alerts - newser.com
Vistagen Therapeutics Inc. stock momentum explainedWeekly Loss Report & High Return Stock Watch Alerts - newser.com
Combining machine learning predictions for Vistagen Therapeutics Inc.July 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
VistaGen Therapeutics’ (VTGN) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Published on: 2025-10-10 09:33:10 - newser.com
Using Ichimoku Cloud for Vistagen Therapeutics Inc. technicalsExit Point & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-10-10 04:25:39 - newser.com
VistaGen Therapeutics (NASDAQ:VTGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
What MACD and RSI say about Vistagen Therapeutics Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
We Think Vistagen Therapeutics (NASDAQ:VTGN) Needs To Drive Business Growth Carefully - Sahm
Advanced analytics toolkit walkthrough for Vistagen Therapeutics Inc.July 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
High Stakes Ahead: Vistagen's Fasedienol Trials Could Make Or Break The Story - RTTNews
Sector ETF performance correlation with Vistagen Therapeutics Inc.July 2025 Closing Moves & High Yield Stock Recommendations - newser.com
How moving averages guide Vistagen Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - newser.com
Detecting price anomalies in Vistagen Therapeutics Inc. with AIMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Has Vistagen Therapeutics Inc. found a price floorJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com
Understanding Vistagen Therapeutics Inc.’s price movement2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Full technical analysis of Vistagen Therapeutics Inc. stockJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
Vistagen Therapeutics Inc. stock daily chart insightsJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
What’s the recovery path for long term holders of Vistagen Therapeutics Inc.Share Buyback & Verified Momentum Stock Watchlist - newser.com
How high can Vistagen Therapeutics Inc. stock go2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Vistagen Therapeutics Inc Stock Analysis and ForecastHigh Frequency Trading Trends & Access High Yield Alerts - earlytimes.in
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):